首页 > 市场调查报告书 > 医疗设备

伤口护理

创伤护理生物製药市场规模、份额和成长分析（按产品类型、伤口类型、最终用户和地区划分）—2026-2033年产业预测

市场调查报告书

商品编码

1899688

创伤护理生物製药市场规模、份额和成长分析（按产品类型、伤口类型、最终用户和地区划分）—2026-2033年产业预测

Wound Care Biologics Market Size, Share, and Growth Analysis, By Product (Biological Skin Substitutes, Topical Agents), By Wound Type (Ulcers, Surgical & Traumatic Wounds), By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球创伤护理生物製药市场规模预计在 2024 年达到 18.8 亿美元，从 2025 年的 19.8 亿美元增长到 2033 年的 29.7 亿美元，在预测期（2026-2033 年）内复合年增长率为 5.2%。

受技术进步和对创新癒合方案日益增长的需求驱动，全球创伤护理生物製药市场正经历显着扩张。包括生长因子、细胞激素和干细胞在内的生物製药已被证明能有效治疗慢性伤口和糖尿病溃疡等复杂疾病。慢性病发病率的上升和人口老化导致伤口癒合延迟，是推动该市场成长的重要因素。此外，个人化医疗和先进疗法的发展趋势也促使医疗机构将生物製药应用于临床治疗，以改善患者预后。然而，市场仍面临许多挑战，例如高成本限制了生物製剂的普及、严格的监管障碍、来自传统治疗方法的竞争，以及某些地区医疗专业人员对生物製剂认知不足等，这些都可能影响整体市场渗透率。

全球创伤护理生物製药市场驱动因素

慢性伤口（包括糖尿病足溃疡和压疮）盛行率的不断上升，在推动创伤护理生物製药市场成长方面发挥关键作用。这些生物製剂提供创新有效的治疗方案，能够加速复杂伤口的癒合过程。随着受这些疾病影响的患者人数不断增加，对先进伤口管理解决方案的需求也日益增长，对生物製剂的需求仍然强劲。这一趋势凸显了创伤护理生物製药在应对慢性创伤治疗相关重大挑战方面的重要作用。

限制全球创伤护理生物製药市场的因素

生物创伤护理产品严格的监管核准流程带来了许多挑战，导致产品上市时间延长。这项复杂且往往耗时的程序不仅延长了创新解决方案惠及消费者的时间，也增加了製造商的研发成本。企业在应对复杂的合规和检验环境时，可能面临财务限制和资源分配方面的挑战，这会影响其竞争力以及推出新产品的能力。因此，这些监管障碍严重阻碍因素了全球创伤护理生物製药市场的成长。

全球创伤护理生物製药市场趋势

全球创伤护理生物製药市场正经历着向个人化医疗的显着转变，这一转变旨在根据个别患者的需求和特定的伤口特征量身定制治疗通讯协定。这种转变反映了更广泛的医疗保健趋势，即优先考虑个人化治疗方法并提高创伤护理干预措施的有效性。生物製药因其能够促进个人化癒合解决方案而日益受到认可，它们利用先进技术和生物材料来适应不同的伤口情况。随着医疗保健提供者寻求透过标靶方法来改善患者预后，对支持个人化策略的创新创伤护理生物製药的需求预计将显着增长。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Smith & Nephew（United Kingdom）
Integra LifeSciences（United States）
Organogenesis Holdings Inc.（United States）
MiMedx Group, Inc.（United States）
Osiris Therapeutics, Inc.（United States）
Aroa Biosurgery（New Zealand）
Avita Medical（Australia）
Derma Sciences, Inc.（United States）
Alliqua BioMedical, Inc.（United States）
Amnio Technology, LLC（United States）
Tissue Regenix Group plc（United Kingdom）
CollPlant Biotechnologies Ltd.（Israel）
RenovaCare, Inc.（United States）
PolarityTE, Inc.（United States）
Cytori Therapeutics, Inc.（United States）
Histogenics Corporation（United States）
Vericel Corporation（United States）
RepliCel Life Sciences Inc.（Canada）

结论与建议

简介目录

Product Code: SQMIG35H2221

Global Wound Care Biologics Market size was valued at USD 1.88 Billion in 2024 and is poised to grow from USD 1.98 Billion in 2025 to USD 2.97 Billion by 2033, growing at a CAGR of 5.2% during the forecast period (2026-2033).

The global wound care biologics market is witnessing notable expansion, fueled by technological advancements and increasing demand for innovative healing solutions. Biologics, which encompass growth factors, cytokines, and stem cells, are proving effective for treating complex conditions like chronic wounds and diabetic ulcers. The rising incidence of chronic diseases and an aging population more prone to slow-healing wounds are significant contributors to this market's growth. Additionally, the trend towards personalized medicine and advanced therapies is prompting healthcare providers to integrate biologics for enhanced patient outcomes. However, challenges remain, including high costs that limit accessibility, stringent regulatory barriers, competition from traditional treatments, and insufficient awareness among healthcare professionals in certain areas, which could impact overall market penetration.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Wound Care Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Wound Care Biologics Market Segments Analysis

Global Wound Care Biologics Market is segmented by Product, Wound Type, End User and region. Based on Product, the market is segmented into Biological Skin Substitutes and Topical Agents. Based on Wound Type, the market is segmented into Ulcers, Surgical & Traumatic Wounds and Burns. Based on End User, the market is segmented into Hospitals, Ambulatory Surgery Centers and Burn Care Centers & Wound Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Wound Care Biologics Market

The rising prevalence of chronic wounds, including diabetic foot ulcers and pressure ulcers, plays a crucial role in propelling the growth of the wound care biologics market. These biologic products provide innovative and effective therapeutic solutions that enhance the healing process for complex wound cases. As the need for advanced wound management solutions continues to increase due to the growing patient population affected by these conditions, the demand for biologic interventions remains robust. This trend highlights the essential role that wound care biologics play in addressing the significant challenges associated with chronic wound healing.

Restraints in the Global Wound Care Biologics Market

The stringent regulatory approval process for biologic wound care products presents significant challenges that can hinder their timely market entry. This complex and often lengthy procedure not only prolongs the timeline for bringing these innovative solutions to consumers but also escalates development costs for manufacturers. As companies navigate the intricate landscape of compliance and validation, they may face financial constraints and resource allocation issues, which can affect their competitiveness and ability to introduce new products. Consequently, these regulatory hurdles serve as a notable restraint on the growth of the global wound care biologics market.

Market Trends of the Global Wound Care Biologics Market

The Global Wound Care Biologics market is experiencing a notable trend towards personalized medicine, emphasizing the customization of treatment protocols to align with individual patient needs and specific wound characteristics. This shift reflects a broader healthcare movement that prioritizes tailored therapies, enhancing the efficacy of wound care interventions. Biologics are increasingly recognized for their ability to facilitate individualized healing solutions, leveraging advanced technologies and biomaterials that adapt to diverse wound profiles. As healthcare providers seek to improve patient outcomes through targeted approaches, the demand for innovative wound care biologics that support personalized strategies is poised for significant growth.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Wound Care Biologics Market Size by Product & CAGR (2026-2033)

Market Overview
Biological Skin Substitutes
- Human Donor Tissue-derived Products
- Acellular Animal-derived Products
- Biosynthetic Products
Topical Agents

Global Wound Care Biologics Market Size by Wound Type & CAGR (2026-2033)

Market Overview
Ulcers
- Diabetic Foot Ulcers
- Venous Ulcers
- Pressure Ulcers
- Other Ulcers
Surgical & Traumatic Wounds
Burns

Global Wound Care Biologics Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Ambulatory Surgery Centers
Burn Care Centers & Wound Clinics

Global Wound Care Biologics Market Size & CAGR (2026-2033)

North America (Product, Wound Type, End User)
- US
- Canada
Europe (Product, Wound Type, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Wound Type, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Wound Type, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Wound Type, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Smith & Nephew (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Integra LifeSciences (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Organogenesis Holdings Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MiMedx Group, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Osiris Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aroa Biosurgery (New Zealand)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avita Medical (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Derma Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alliqua BioMedical, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amnio Technology, LLC (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tissue Regenix Group plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CollPlant Biotechnologies Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RenovaCare, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PolarityTE, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cytori Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Histogenics Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vericel Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RepliCel Life Sciences Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments